生命科学资讯

Chutes & Ladders—Sanofi's stunning CEO switch

Integra LifeSciences cuts roles as 65 staffers impacted from Princeton, N.J., site

Moderna R&D spend shrunk 31% in 2025 amid major pipeline reorg

Lundbeck migraine prevention drug succeeds in Phase 2, advancing new therapy class

Moderna's flu shot dilemma muddies 2028 break-even guidance

10X Genomics stock price target raised to $22 from $20 at Canaccord Genuity - Investing.com

FDA removes box warning for 6 menopausal therapies

Lilly stockpiles $1.5B worth of weight loss pill ahead of US approval

Immunic's private placement; Vertex's cystic fibrosis data in young kids

Quantx raises $85M to advance oral immunology drugs

NME Digest: Q4 2025

10x Genomics, Inc. (NASDAQ:TXG) Q4 2025 Earnings Call Transcript - Insider Monkey

Sanofi, looking for more ‘rigor,’ swaps CEO Hudson for ex-Merck KGaA chief

Ovid takes another big swing in neuroscience under a new CEO

New CBL-B inhibitors reported in Aurigene Oncology patent

Nanjing Anji Biotechnology synthesizes new OGDH inhibitors

Salubris Pharma divulges new dual ETA/AT1 antagonists

New South Capital Management Inc. Sells 2,413 Shares of Thermo Fisher Scientific Inc. $TMO - MarketBeat

Lonza Refreshes Board with Technology-Focused Appointments in Governance Overhaul - TipRanks

Ultragenyx lays off 10% of workforce as FDA continues to stall gene therapy approval plans